Today we analyze an article on osteochondroses of the lower limb in developmental age
In the clinic, the word "osteochondrosis" often comes with a double risk: scaring families more than necessary and, at the same time, making us lose sight of the fact that we are talking about different conditions. The review by Beber, Groff, and Doyle is useful precisely because it brings order: osteochondroses are not a single diagnosis, but a heterogeneous group of pathologies related to endochondral ossification in developmental age. They can involve epiphyses, physes, or apophyses; they are often multifactorial and, in many cases, overuse (sports, running, jumping, rapid growth) plays a role in the emergence of symptoms.
Reviewed article
Beber SA, Groff KD, Doyle SM. From growing pains to growing evidence: a 2025 update on novel insights in lower limb osteochondroses. Current Opinion in Pediatrics. Epub 2025 Oct 22; 2026 Feb 1;38(1):100–107. PMID: 41133728. DOI: 10.1097/MOP.0000000000001523.
The first message, simple but clinically fundamental, is that many of these conditions often have a self-limiting course and are managed with conservative treatment, while a more selected portion may require surgical interventions. This is not an invitation to "let things slide," but to do what we might call intelligent observation: understanding who can be followed with peace of mind and who, instead, deserves a stricter path or more timely decisions.
The most interesting part of the review, however, is the shift in focus: innovation is not just "a new therapy," but above all the search for tools that improve diagnosis and prognosis. The authors cite the growing interest in advanced approaches and also in support tools based on machine learning: the goal is to refine the evaluation and better stratify risk, because in many osteochondroses the real clinical question is not only "what pathology is it?", but "what is the probability of it evolving well with conservative treatment?" and "what signs tell me that I need to change strategy?".
On the hip side, Perthes disease is cited as an example where imaging can evolve towards more refined evaluations. In particular, the review mentions perfusion magnetic resonance imaging as a tool studied to obtain a more precise evaluation with potential prognostic value. It is important to correctly interpret this point: it does not mean that perfusion should become a routine examination for everyone, nor that it replaces clinical and radiographic experience. Rather, it signals a direction: trying to measure more accurately aspects that can correlate with the evolution of the femoral head and thus help in counseling, follow-up, and, in appropriate contexts, in therapeutic choices.
Moving to the knee, the review mentions Osgood-Schlatter and cites leukocyte-rich platelet-rich plasma (LR-PRP) as an emerging treatment, described as promising for improving pain and function. This is a point that must be handled with care, especially in communication with families: Osgood-Schlatter, in the vast majority of cases, remains a condition manageable with conservative treatment and load modulation, and often has a favorable course. The fact that the literature explores injectable options does not automatically transform LR-PRP into a standard. It indicates, rather, that there is a range of more symptomatic or more difficult-to-manage cases where additional solutions are being sought, and that comparative data and follow-up are needed to truly define indications, lasting benefits, and limitations.
Finally, for Freiberg's disease, the authors emphasize that recent literature is trying to clarify the "optimal" surgical management. This is another sign of how the field is moving: when conservative treatment is not enough, the discussion is no longer just "to operate or not," but "which technique, for which stage, with what realistic functional goal."
Conclusions
This review functions as a compass: it confirms that many osteochondroses are often self-limiting and that conservative treatment remains central, but it draws attention to three directions of development: improvement of prognosis and risk stratification, more sophisticated imaging in selected cases (such as perfusion magnetic resonance imaging in Perthes disease), and evaluation of emerging therapies (such as LR-PRP in Osgood-Schlatter) or more targeted surgical approaches (Freiberg). Integration into practice requires critical reading of the underlying studies and solid data on outcomes and follow-up before transforming these hypotheses into shared standards.
Disclaimer: This content is for informational purposes only and does not replace an individual clinical evaluation.
